Vutrisiran (AMVUTTRA)
Small interfering RNA (siRNA) therapy, transthyretin (TTR)-directed gene silencer
Vutrisiran (AMVUTTRA)
Forms and strengths
Form: TabletStrength: 25 mg/0.5 mL
References
Indication
- Vutrisiran (AMVUTTRA) is used to treat stage 1 or stage 2 polyneuropathy in adults with hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis).
- Vutrisiran is also used to treat cardiomyopathy in adults with wild-type or hereditary transthyretin amyloidosis (wtATTR or hATTR amyloidosis).
- Treatment should be started as early as possible in the disease course to help prevent the buildup of disability.
Pregnancy
- There are no data on vutrisiran use in pregnant women, and the effects of reduced maternal TTR or vitamin A levels on the fetus are unknown.
- Vutrisiran is not recommended during pregnancy, since both too-high and too-low vitamin A levels during early pregnancy may increase the risk of fetal malformation.
- Pregnancy should be ruled out before starting treatment, and women of childbearing potential should use effective contraception during treatment.
- If pregnancy is planned, vutrisiran and vitamin A supplementation should be stopped, and serum vitamin A levels monitored until they return to normal before conception is attempted.
- If pregnancy occurs unexpectedly during treatment, vutrisiran should be discontinued.
- There are no human data on vutrisiran's effect on fertility; animal studies showed no impact on male or female fertility.
Breastfeeding
- It is not known whether vutrisiran passes into human breast milk or affects milk production.
- Breast milk is an important source of vitamin A for infants, and vutrisiran's effect on vitamin A levels in breast milk has not been studied.
- The benefits of breastfeeding should be weighed against the mother's clinical need for treatment and any potential risk to the infant.
Geriatrics
- No overall differences in safety or effectiveness were observed between patients 65 years of age or older and younger patients, though greater sensitivity in some older individuals cannot be ruled out.
- No dose adjustment is required based on age alone.
- A substantial proportion of patients in the polyneuropathy and cardiomyopathy clinical trials were 65 years or older, with consistent pharmacokinetics and effectiveness seen across age groups in both studies.
Pediatrics
- Safety and efficacy in patients under 18 years of age have not been studied, and Health Canada has not authorized a pediatric indication.
Dosage & Administration
- The recommended dose is 25 mg given by subcutaneous injection once every 3 months.
- Vutrisiran must be administered by a healthcare professional, using the prefilled syringe in the abdomen, thigh, or upper arm.
- If stored refrigerated, the prefilled syringe should be allowed to warm to room temperature for about 30 minutes before use.
- Visually inspect the syringe and solution before injecting; do not use if the syringe is damaged or the solution is cloudy, discoloured, or contains particles.
- Avoid injecting within 5 cm of the navel, or into scar tissue or skin that is red, inflamed, or swollen.
- No dose adjustment is needed for mild or moderate hepatic or renal impairment; vutrisiran has not been studied in severe hepatic or renal impairment, or in end-stage renal disease.
- Patients switching from another TTR-reducing therapy should be monitored closely, given limited experience with switching regimens.
- There is limited data with vutrisiran in patients who have progressed to advanced heart failure (NYHA Class IV, or Class III with stage 3 ATTR amyloidosis), though these patients may remain on treatment at the physician's discretion.
- If a dose is missed, it should be given as soon as possible, with the next dose then scheduled 3 months from that administration.
Overdose
If overdose is suspected, seek emergency medical attention immediately or contact your regional Poison Control Centre without delay.
- Clinical experience with vutrisiran overdose is limited, and the product monograph does not describe a specific toxidrome.
- Management involves monitoring the patient for any signs or symptoms of adverse effects and providing appropriate treatment.
Common side effects
- Pain in the arms, hands, legs, or feet is common.
- Joint pain (arthralgia) is common.
- Shortness of breath (dyspnea) may occur.
- Bruising at the injection site may occur.
- Redness at the injection site may occur.
- Pain at the injection site may occur.
- Itching (pruritus) at the injection site may occur.
- Warmth at the injection site may occur.
Serious side effects
Serious side effects require immediate discussion with the prescriber or emergency care.
- Reduced vitamin A levels occur in essentially all patients due to vutrisiran's effect on TTR, which normally carries vitamin A in the blood.
- Vitamin A deficiency symptoms, including reduced night vision, persistent dry eyes, eye inflammation, corneal thickening, or corneal ulceration or perforation, can occur and warrant referral to an eye specialist.
- Standard blood tests for vitamin A do not reflect total body vitamin A and should not be used to guide supplementation while on treatment.
- A small number of patients develop anti-drug antibodies, though these have not been associated with reduced effectiveness or safety concerns.
- Seek urgent medical attention for a severe allergic reaction, or for any sudden or worsening change in vision.
Use with caution
- Daily vitamin A supplementation at the recommended daily allowance is advised for all patients taking vutrisiran, since the drug lowers blood vitamin A levels.
- Use with caution in patients with pre-existing eye disease related to amyloidosis, since it can be difficult to distinguish from vitamin A deficiency symptoms; referral to an ophthalmologist is recommended if new ocular symptoms develop.
- Women of childbearing potential should use effective contraception during treatment, given the teratogenic risk associated with unbalanced vitamin A levels.
- Serum vitamin A levels may remain reduced for more than 12 months after the last dose, which should be considered when planning a pregnancy.
- No formal studies have assessed vutrisiran's effect on the ability to drive or operate machinery, though it is not expected to have a significant effect.
Contraindications
- Contraindicated in patients with a history of severe hypersensitivity to vutrisiran or to any ingredient in the formulation.
Drug interactions
- No clinical drug-drug interaction studies have been performed with vutrisiran.
- Vutrisiran is not expected to cause drug interactions through cytochrome P450 enzymes or drug transporters, based on its metabolism by endonucleases and exonucleases rather than CYP pathways.
- No formal studies on drug-behavioural interactions have been performed with vutrisiran.
Food interactions
- Not applicable; vutrisiran is given by subcutaneous injection, and interactions with food have not been established for this route.
- Interactions with herbal products have not been established.
Time of administration
- Given as a subcutaneous injection by a healthcare professional once every 3 months; timing is not tied to meals or time of day.
Storage
- Store at 2°C to 30°C in the original carton until ready for use.
- Do not freeze.
- Do not dispose of unused medicine via wastewater or household waste; ask a healthcare professional how to dispose of it safely.
Patient take-away
- Vutrisiran (AMVUTTRA) is a subcutaneous injection given every 3 months by a healthcare professional to treat nerve or heart complications of transthyretin (TTR) amyloidosis.
- Daily vitamin A supplementation is needed throughout treatment because vutrisiran lowers blood vitamin A levels.
- Report any change in vision, night vision problems, or persistent dry eyes to your healthcare professional.
- Effective contraception is needed during treatment, since imbalanced vitamin A levels can harm a developing baby.
- Injection-site reactions, joint pain, and limb pain are common but usually mild.